Bausch Health: RED-C Failure Leaves Blockbuster Xifaxan Without A Successor
Source: SeekingAlpha
2026-01-23 14:35:21 ET
Bausch Health Companies Inc. ( BHC ) stock is off nearly 10% in intraday trading after reporting that its Phase 3 program evaluating "next-gen" rifaximin to delay the first episode of hepatic encephalopathy in patients with cirrhosis failed....
Read the full article on Seeking Alpha
For further details see:
Bausch Health: RED-C Failure Leaves Blockbuster Xifaxan Without A Successor
Bausch Health Companies Inc.
NASDAQ: BHC:CC
BHC:CC Trading
-0.34% G/L:
$5.88 Last:
1,784,767 Volume:
$5.90 Open:
BHC:CC Latest News
February 23, 2026 08:00:00 am
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
February 19, 2026 08:00:00 am
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
